ClinicalTrials.gg
CompletedNCT02553928Updated Mar 14, 2019Results posted

Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer

A Phase 4 interventional study of Memantine (once daily) and Memantine (twice daily) in Alzheimer Dementia (AD), sponsored by H. Lundbeck A/S. Completed at 6 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by H. Lundbeck A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing memantine in Alzheimer Disease — 1 open to participants now, 2 under way, none of them phase 3. Memantine · Alzheimer Disease.

Enrollment
20th of 34
62 · median 90
Started
2015
the only one that year
Phase 4
21 of 34
none open now
Registered
27th of 34
by date
Lead sponsor
4 of 34
H. Lundbeck A/S

Among the 34 studies testing memantine in Alzheimer Disease, this one is the 20th largest by enrollment, is the only one that started in 2015, is one of 21 in phase 4, and was the 27th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 34 studies testing memantine in Alzheimer Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About memantine

Memantine: first FDA approval 2003 (NAMENDA), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing memantine in Alzheimer Disease, or all of them as a file.
02

Study summary

Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.

03

Conditions studied

  • Alzheimer Dementia (AD)

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient has a knowledgeable and reliable caregiver who will accompany the patient to all clinical visits during the study.
  • The patient has a diagnosis of probable AD consistent with the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
  • The patient has a (MMSE) score ≥ 5 and ≤ 18 at Screening visit
  • The dose of Memantine has been stable at 20 mg once a day for at least 3 month prior to screening

Exclusion criteria

Exclusion Criteria:

  • The patient has one or more of the following conditions: Evidence and/or history of any neurodegenerative disease or other serious neurological disorders other than Alzheimer's disease including, but not limited to, Lewy body dementia, Fronto-Temporal dementia, Parkinson's disease, Huntington's disease, major cortical stroke, Multiple Sclerosis, major head trauma and primary or secondary cerebral neoplasm.
  • The patient has a modified Hachinski ischemia score greater than 4 at the screening visit.
  • The patient has any current psychiatric disorder or Axis I disorder (™ criteria), established as the primary diagnosis, other than AD
  • The patient is currently receiving treatment with an unstable dose of acetyl cholinesterase inhibitor

Other protocol defined inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Memantine (once daily)

    Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally

    Drug: Memantine (once daily)

  • Experimental
    Memantine (twice daily)

    Memantine 10 mg twice daily, tablets, orally AND Placebo tablets twice daily, orally

    Drug: Memantine (twice daily)

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of patients who reported adverse events

    Time frame: baseline to week 16 (end of study)

Secondary outcomes

  1. ADCS - CGIC Score at Week 12

    The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) is a semi-structured interview designed to assess clinically relevant changes in patients with Alzheimer's disease. Items in the ADCS-CGIC interview provide general information, and information about cognition, behaviour, social and daily functioning. Responses to ADCS-CGIC interview result in a global clinical judgement of severity (at baseline) and clinically relevant change at subsequent visits. Severity rated at baseline is only used for reference. The severity at baseline is rated on a 7-point Likert-type scale from 1(normal, not ill at all) to 7 (among the most extremely ill patients). The ADCS-CGIC relevant change is rated on a 7-point Likert-type scale from 1 (marked improvement) to 7 (marked worsening).

    Time frame: ADCS - CGIC score at Week 12

07

Results

Posted Mar 14, 2019

Participant flow

Participant flow — Overall Study
MilestoneMemantine (Once Daily)Memantine (Twice Daily)
Started3032
Completed2829
Not completed23
Withdrew: Adverse event21
Withdrew: Lost to follow-up01
Withdrew: Administrative reason(s)01

Outcome measures

PrimaryAdverse Events

Number of patients who reported adverse events

Time frame:
baseline to week 16 (end of study)
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsMemantine (Once Daily)Memantine (Twice Daily)
Adverse Events1516
SecondaryADCS - CGIC Score at Week 12

The Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) is a semi-structured interview designed to assess clinically relevant changes in patients with Alzheimer's disease. Items in the ADCS-CGIC interview provide general information, and information about cognition, behaviour, social and daily functioning. Responses to ADCS-CGIC interview result in a global clinical judgement of severity (at baseline) and clinically relevant change at subsequent visits. Severity rated at baseline is only used for reference. The severity at baseline is rated on a 7-point Likert-type scale from 1(normal, not ill at all) to 7 (among the most extremely ill patients). The ADCS-CGIC relevant change is rated on a 7-point Likert-type scale from 1 (marked improvement) to 7 (marked worsening).

Time frame:
ADCS - CGIC score at Week 12
Reported as:
Mean · units on a scale
ADCS - CGIC Score at Week 12
units on a scaleMemantine (Once Daily)Memantine (Twice Daily)
ADCS - CGIC Score at Week 123.92 ± 0.143.60 ± 0.14
Statistical analysis
  • Memantine (Once Daily) vs Memantine (Twice Daily) · ANCOVA · p = 0.097 (Based on full analysis set) · Mean difference (final values): 0.32 · 95% CI -0.06 to 0.69The comparison is to BID memantine.

Adverse events

Collected over Baseline to week 16 (end of study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Memantine (Once Daily)—0/30 (0%)6/30 (20%)
Memantine (Twice Daily)—1/32 (3.1%)2/32 (6.3%)
Most frequent serious events
Most frequent serious events
EventMemantine (Once Daily)Memantine (Twice Daily)
Spinal compression fractureInjury, poisoning and procedural complications0/301/32
Most frequent other events
Most frequent other events
EventMemantine (Once Daily)Memantine (Twice Daily)
HypertensionVascular disorders2/300/32
Sinus bradycardiaCardiac disorders2/300/32
White blood cell count decreasedInvestigations2/300/32
Urinary incontinenceRenal and urinary disorders0/302/32

Baseline characteristics

Age, Continuous
Age, Continuous(years)Memantine (Once Daily)Memantine (Twice Daily)Total
Mean69.1 ± 9.370.3 ± 8.169.7 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Memantine (Once Daily)Memantine (Twice Daily)Total
Female171734
Male131528
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Memantine (Once Daily)Memantine (Twice Daily)Total
Asian303262
MMSE Total Score
MMSE Total Score(units on a scale)Memantine (Once Daily)Memantine (Twice Daily)Total
Mean11.4 ± 4.211.4 ± 4.511.4 ± 4.3
Modified Hachinski Ischemia Total Score
Modified Hachinski Ischemia Total Score(units on a scale)Memantine (Once Daily)Memantine (Twice Daily)Total
Mean1.6 ± 1.21.8 ± 0.91.7 ± 1.0
Duration of Alzheimer's Disease
Duration of Alzheimer's Disease(years)Memantine (Once Daily)Memantine (Twice Daily)Total
Mean2.1 ± 1.92.3 ± 1.92.2 ± 1.9
08

Study locations

6 sites
  • CN001
    Beijing, China
  • CN006
    Fujian, China
  • CN004
    Shandong, China
  • CN002
    Tianjin, China
  • CN007
    Xi'an, China
  • CN003
    Zhejiang, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2015
First posted
Sep 18, 2015
Start
Oct 2015
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Mar 14, 2019
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02553928
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Sep 18, 2015
Start date
Oct 2015
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Mar 14, 2019
Last update
Mar 14, 2019

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Memantine

Start the discussion